Publications by authors named "Ming Y He"

Claim this Profile
R
Radiotherapy in triple-negative breast cancer: Current situation and upcoming strategies.
Ming Yuan He, Chloé Rancoule, Amel Rehailia-Blanchard, Sophie Espenel, Jane-Chloé Trone

Crit Rev Oncol Hematol· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: From IB2 to IIIB locally advanced cervical cancers: report of a ten-year experience.
Sophie Espenel, Max-Adrien Garcia, Jane-Chloé Trone, Elodie Guillaume, Annabelle Harris, Ming Yuan He, Guy De Laroche

Radiat Oncol· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
From IB2 to IIIB locally advanced cervical cancers: report of a ten-year experience.
Sophie Espenel, Max-Adrien Garcia, Jane-Chloé Trone, Elodie Guillaume, Annabelle Harris, Ming Yuan He, Guy De Laroche

Radiat Oncol· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vaginal metastasis of renal clear-cell cancer.
Amel Rehailia-Blanchard, Adekube Morel, Chloé Rancoul, Ming Yuan He, Nicolas Magné

Gulf J Oncolog· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Shape selectivity extending to ordered supermicroporous aluminosilicates.
Wen Hua Fu, Xiao Min Liang, Haidong Zhang, Yi Meng Wang, Ming Yuan He

Chem Commun (Camb)· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COX-2 inhibition improves immune system homeostasis and decreases liver damage in septic rats.
Bin Li, Yu Min Li, Xun Li, Bin Shi, Ming Yan He, Mitchell S Wachtel

J Surg Res· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, structure-activity relationship, and pharmacokinetic profile of pyrazole-based indoline factor Xa inhibitors.
Jeffrey G Varnes, Dean A Wacker, Irina C Jacobson, Mimi L Quan, Christopher D Ellis, Ming Y He, Kan He

Bioorg Med Chem Lett· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
1-[3-Aminobenzisoxazol-5'-yl]-3-trifluoromethyl-6-[2'-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1']-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa.
Donald J P Pinto, Michael J Orwat, Mimi L Quan, Qi Han, Robert A Galemmo, Christopher Ellis, Ming Y He, Kan He

Bioorg Med Chem Lett· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor.
Mimi L Quan, Patrick Y S Lam, Qi Han, Donald J P Pinto, Ming Y He, Christopher D Ellis, Christopher A Teleha

J Med Chem· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonbenzamidine isoxazoline derivatives as factor Xa inhibitors.
Mimi L Quan, Christopher D Ellis, Ming Y He, Ann Y Liauw, Patrick Y S Lam, Matthew R Wright

Bioorg Med Chem Lett· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonbenzamidine tetrazole derivatives as factor Xa inhibitors.
Mimi L Quan, Christopher D Ellis, Ming Y He, Ann Y Liauw, Francis J Woerner, Matthew R Wright

Bioorg Med Chem Lett· February 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis